Search
Lung Cancer Backgrounder_0.pdf
Lung_Cancer_Backgrounder.pdf
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
Ingelvac MycoFLEX®
For the active immunisation of pigs from the age of three weeks to reduce lung lesions following infections with Mycoplasma hyopneumoniae.
Do you take periodontal disease in dogs seriously? We do!
Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Dan
People with Type 2 diabetes (T2D) have an increased risk of heart disease
The geography of pet parasites is changing
Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
Patient Documentary
People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Our mission in cardiovascular, renal, and metabolic care
Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis